Overview

Phase I Multiple-Ascending Dose (Japan)

Status:
Completed

Trial end date:
2008-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following once daily oral doses of 2.5, 10, and 20 mg of dapagliflozin in diabetic Japanese subjects administered for 14 days

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin